News
Fertility drug improves live birth rates in women undergoing IVF

New research has demonstrated the effectiveness of a non-hormonal drug in increasing embryo implantation, pregnancy and live birth rates among women undergoing IVF and ICSI.
The findings, presented at the ESHRE 40th annual meeting in Amsterdam, represent a significant step toward the first therapeutic tool to increase embryo implantation and live birth rate success.
Worldwide, one in six people of reproductive age experience infertility in their lifetime. Over three million IVF cycles are performed annually and yet, despite advancing IVF technologies, embryo implantation failure remains a significant challenge.
In response to this unmet need, researchers have unveiled the promising findings of their Phase 2 clinical trial, OXOART2. The trial, conducted across 28 centres in Europe, evaluated OXO-001, a drug that acts directly on the endometrium to improve embryo implantation and pregnancy rates.
The study analysed 96 women aged up to 40 years old who underwent a single embryo transfer, 42 receiving placebo and 54 receiving a daily dose of OXO-001. Treatment began one menstrual cycle before the embryo transfer cycle and continued until five weeks after the transfer.
Statistically significant improvements were observed in biochemical pregnancy rates – an early detection of pregnancy – with rates of 75.9 per cent in the OXO-001 group compared to 52.4 per cent in the placebo group.
Clinically relevant improvements were also seen in clinical pregnancy rates and in ongoing pregnancy rates, being a +14.3 absolute increase (50.0 per cent for OXO-001 vs. 35.7 per cent for placebo) and a +10.6 absolute increase (46.3 per cent for OXO-001 vs 35.7 per cent for placebo) respectively.
Most importantly, there was an absolute increase of +6.9 in live birth rates (42.6 per cent for OXO-001 vs. 35.7 per cent for placebo).
Dr Agnès Arbat, OXOLIFE’s CEO and CMO, said: “From scientific societies, key opinion leaders, clinicians and patients, we know that an absolute increase of more than five percentage points in ongoing pregnancy is considered clinically meaningful.
“We observed an increase higher than +9, giving renewed hope to patients and the scientific community. We look forward to advancing this promising treatment through the next phases of clinical development.”
The occurrence of side effects was similar in both groups. The most common side effects were headaches, nausea, vomiting, gastrointestinal issues and dizziness, most of which were mild to moderate.
In the six-month follow-up, the babies indicated good development with no differences with placebo, the research showed and overall, OXO-001 was well tolerated.
Dr Ignasi Canals, CSO of OXOLIFE said: “We are thrilled with the results of this trial, which highlight OXO-001’s potential to become the first therapeutic treatment to increase embryo implantation success, with a non-hormonal drug using a new mechanism of action, acting directly on the endometrium.”
Professor Dr Karen Sermon, chair of ESHRE, added: “Despite continuous developments in ovarian stimulation, embryo manipulation and culture, improving live birth rates in medically assisted reproduction has been incremental at best.
“A jump of nearly seven per cent is very good news for our patients, and hopefully this can be confirmed in larger patient groups.”
To receive the Femtech World newsletter, sign up here.
Fertility
Toxins and climate harms having ‘alarming’ effect on fertility, research warns

Simultaneous exposure to toxic chemicals and climate-related heat may be worsening fertility harms across humans and wildlife, research suggests.
The review of scientific literature looks at how endocrine-disrupting chemicals, often found in plastic, together with climate-related effects such as heat stress, are each linked to lower fertility and fecundity, meaning the ability to reproduce, across species including humans, wildlife and invertebrates.
Though the reproductive harms of each issue in isolation are well studied, there is little research on what happens when living organisms are exposed to both.
“Together, the two issues are likely to pose a greater threat to fertility, and the additive effect is “alarming”, said Susanne Brander, a study lead author and courtesy faculty at Oregon State University.
“You’re not just getting exposed to one, but two, stressors at the same time that both may affect your fertility, and in turn the overall impact is going to be a bit worse,” Brander said.
The paper looked at 177 studies.
Shanna Swan, a co-author on the new paper, co-produced a 2017 study that found sperm levels among men in western countries had fallen by more than 50 per cent over four decades. Other research has suggested human fertility has been declining at a similar rate.
The University of Washington’s Institute for Health Metrics and Evaluation has previously said the world was approaching a “low-fertility future”, with more than three quarters of countries below replacement rate by 2050.
The new paper’s authors focused on the effects of endocrine-disrupting chemicals and substances, including microplastics, bisphenol, phthalates and PFAS.
These are thought to cause a range of serious reproductive problems, disrupt hormones and be a potential driver of falling fertility.
Brander said the harms linked to these chemicals are often similar across organisms, from invertebrates to humans.
Phthalates, for example, have been linked to altered sperm shape in invertebrates, spermatogenesis in rodents, meaning sperm production, and reduced sperm counts in humans.
PFAS are also thought to affect sperm quality, and both have been linked to hormone disruption.
The chemicals are widespread in consumer goods, so people are often regularly exposed.
Meanwhile, previous research has shown how rising temperatures, lower oxygen levels and heat stress, among other effects linked to climate change, may also worsen infertility.
Heat stress has been found to affect human hormones, and is linked to spermatogenesis in rodents and bulls.
Research shows temperature also plays a role in sex determination in fish, reptiles and amphibians.
The species has evolved to choose which sex it produces in part based on temperature, and the heating planet can “push it too far in one direction or the other, which overrides that evolutionary benefit”, Brander said.
Similarly, many endocrine disruptors may alter environmental sex determination.
The study set out some of the overlapping effects of chemical exposure and climate change across taxonomic groups, from invertebrates to humans.
In birds, for example, exposure to increased temperature, PFAS, organochlorines and pyrethroids may each individually cause abnormal sperm, increased fledgling mortality, abnormal testes and population decline.
“What happens if they’re exposed to more than one of those stressors at the same time? There has been little exploration of that question.
“Even if there have not been a lot of studies looking at these simultaneously, if you have two different factors that both cause the same adverse effect, then there’s a likelihood that they are going to be additive,” Brander said.
Katie Pelch, a senior scientist with the Natural Resources Defense Council nonprofit, who was not part of the study, said the authors had reviewed high-quality science.
She said she wanted to see more examples of the overlap in impacts, but agreed with the overall premise.
“It is likely [multiple stressors] would have an additive effect, at very least, even if they have different mechanisms of harm,” Pelch added.
The solution to the systemic problems would involve tackling climate change and reducing the use of toxic chemicals.
The study cites the global reduction in the use of DDT and PCBs achieved under the Stockholm Convention as an example of an effective measure, but Brander said much more is needed.
“There is enough evidence in both areas to act to reduce our impact on the planet,” she said.
Pregnancy
Home blood pressure checks could lower heart risks for new mothers – study
Fertility
Researcher explores weight loss jab impact on PCOS
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Entrepreneur4 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
Opinion4 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Mental health6 days agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says














